It has recently been approved by the American and European medical agencies, based on results from phase 2/3 trials in transfusion dependent MDS patients with ring sideroblasts (RS) or SF3B1 mutations, refractory or not eligible for ESA [92,93]. Here, SF3B1 is linked to myelodysplastic syndrome.